Founded in 2016, the company is a biotech dedicated to research and development of innovative cellular pharmaceuticals. It focuses on the treatment of diseases related to the autoimmune system, nervous system and respiratory system. The company's core competencies include the development of advanced cellular therapeutic products, such as mesenchymal stem cells and induced pluripotent stem cell (iPSC)-derived cells. The company has established five major core technological platforms, including universal iPS platform, iPS differentiation platform, functional gene design and screening platform, bioreactor-based cell production platform, and high stability formulation platform. These platforms underpin the company's in-depth research and product development in the field of cell and gene therapy. In terms of regulatory approvals, the company has secured five clinical trial permits approved by the Center for Drug Evaluation (CDE), as well as three stem cell clinical research project registrations with the National Health Commission or the Central Military Commission of People's Republic of China. The company upholds the values of action orientation, integrity, reliability and excellence, and is committed to advancing the development and application of cellular therapy technologies